Prenatal Diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT)
Yes, prenatal diagnosis of Weber-Rendu-Osler syndrome (HHT) is feasible through molecular genetic testing when a disease-causing mutation has been identified in affected family members, though it is not routinely performed and requires specific clinical circumstances.
Genetic Testing Approach
HHT follows an autosomal dominant inheritance pattern with mutations identified in three main genes: endoglin (ENG, HHT type 1), activin receptor-like kinase-1 (ACVRL1, HHT type 2), and SMAD4 1. The 2020 International HHT Guidelines confirm that genetic testing is available and recommended primarily for asymptomatic persons from families with known HHT 1.
Prerequisites for Prenatal Testing
Prenatal diagnosis requires:
- A known pathogenic mutation identified in an affected family member - this is the critical first step
- Chorionic villus sampling (CVS) at 10-13 weeks or amniocentesis at 15-20 weeks to obtain fetal DNA
- Molecular analysis using either direct mutation sequencing or linkage analysis if the family mutation is known
The 2004 ACCP guidelines specifically state: "Prenatal testing for FPAH [familial pulmonary arterial hypertension associated with HHT] has not been reported, but it is feasible using mutational analysis or linkage in at-risk pregnancies, if the disease-causing mutation has been identified in affected family members" 2. This principle applies to HHT more broadly.
Clinical Context and Limitations
When to Consider Prenatal Testing
The decision for prenatal testing should be made when:
- There is a confirmed HHT diagnosis in the family with identified genetic mutation
- Parents desire definitive prenatal diagnosis for family planning
- There is concern about severe early-onset complications (though rare)
Important Caveats
The clinical utility of prenatal HHT diagnosis is limited because:
Variable penetrance and age of onset: HHT symptoms typically appear in adulthood, with epistaxis developing in an age-related manner and most liver vascular malformations becoming symptomatic around age 30 3
No prenatal intervention available: Unlike some genetic conditions, there are no in-utero treatments that would alter the disease course
Generally favorable prognosis with management: With appropriate screening and preventive treatment after birth, most individuals with HHT can be effectively managed 1
Rare fetal complications: While hepatic arteriovenous malformations causing fetal hemorrhage and necrosis have been reported 4, these are exceptionally rare and not predictable even with genetic diagnosis
Practical Recommendations
For families with known HHT:
- Genetic counseling should be offered before pregnancy to discuss testing options 2, 1
- If prenatal testing is desired, ensure the causative mutation has been identified in the affected parent first
- Coordinate testing through a specialized genetics laboratory experienced with HHT molecular diagnostics
For incidental prenatal findings:
- If hepatic vascular abnormalities are detected on prenatal ultrasound or MRI, consider HHT in the differential diagnosis 4
- Obtain detailed family history for epistaxis, telangiectasias, and visceral arteriovenous malformations
- Postnatal evaluation and genetic testing may be more appropriate than invasive prenatal procedures in most cases
The 2020 International HHT Guidelines emphasize that genetic testing is primarily recommended for diagnosis confirmation and cascade screening of at-risk family members 1, rather than routine prenatal diagnosis, reflecting the generally manageable nature of the condition with appropriate surveillance and treatment.